- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $43M
- 2 Form D · Jul 2025
- 15 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 13 granted · 27 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $42,571,751 | |
| Private capital raised | Form D · SEC | $75,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1184 | Immunaeon Inc. | — | $250K |
| 1185 | Exxel Pharma, INC. | — | $600K |
| 1186 | Vivid Genomics, Inc. | — | — |
| 1187 | Ikena Oncology | — | $43M |
| 1188 | SHIP OF THESEUS, LLC | — | — |
| 1189 | Bridge Therapeutics, Inc. | — | $321K |
| 1190 | BioVaxys Technology Corp. | — | $301K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David BonitaDirector
- Iain DukesDirector
- Jeffrey EcsedyExecutive Officer
- Jean-Francois FormelaDirector
- Owen HughesDirector
- Maria KoehlerDirector
- Mark ManfrediDirector · Executive Officer
- Jotin MarangoExecutive Officer
- Sergio SantillanaExecutive Officer
- Otello StampacchiaDirector
- Richard WoosterDirector
- Michelle ZhangExecutive Officer
Patents
- Mek Inhibitors And Uses Thereofgranted
- SOLID FORMS OF (R)-N-(2-(5-FLUOROPYRIDIN-3-YL)-8-ISOPROPYLPYRAZOLO[1,5-a][1,3,5]TRIAZIN-4-YL)-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-3-AMINE AS ARYL HYDROCARBON RECEPTOR (AHR) INHIBITORSgranted
- Indole Ahr Inhibitors And Uses Thereofgranted
- Aryl Hydrocarbon Receptor (ahr) Agonists And Uses Thereofgranted
- Tead Inhibitors And Uses Thereofgranted
- Mek Inhibitors And Uses Thereofgranted
- Tead Inhibitors And Uses Thereofgranted
- Aryl Hydrocarbon Receptor (ahr) Agonists And Uses Thereofgranted
- SOLID FORMS OF (R)-N-(2-(5-FLUOROPYRIDIN-3-YL)-8-ISOPROPYLPYRAZOLO[1,5-a][1,3,5]TRIAZIN-4-YL)-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-3-AMINE MALEATE AS ARYL HYDROCARBON RECEPTOR (AHR) INHIBITORSgranted
- Ahr Inhibitors And Uses Thereofgranted
- Tead Inhibitors And Uses Thereofgranted
- Indole Ahr Inhibitors And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.